TherapeuticsMD, Inc. (TXMD)
USD 0.9
(1.79%)
USD 0.9
(1.79%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 43.3 Million USD | -52.12% |
| 2022 | 90.45 Million USD | -46.62% |
| 2021 | 169.47 Million USD | -6.68% |
| 2020 | 181.6 Million USD | -31.72% |
| 2019 | 265.98 Million USD | 25.47% |
| 2018 | 211.98 Million USD | 48.0% |
| 2017 | 143.22 Million USD | 0.53% |
| 2016 | 142.47 Million USD | 93.24% |
| 2015 | 73.72 Million USD | 24.8% |
| 2014 | 59.07 Million USD | -4.74% |
| 2013 | 62.01 Million USD | 965.92% |
| 2012 | 5.81 Million USD | 304.39% |
| 2011 | 1.43 Million USD | 207.8% |
| 2010 | 467.41 Thousand USD | -44.99% |
| 2009 | 849.76 Thousand USD | 1461.52% |
| 2008 | 54.41 Thousand USD | -89.01% |
| 2007 | 495.36 Thousand USD | -73.47% |
| 2006 | 1.86 Million USD | 3.3% |
| 2005 | 1.8 Million USD | 66.05% |
| 2004 | 1.08 Million USD | 21.19% |
| 2003 | 898.22 Thousand USD | 19.25% |
| 2002 | 753.21 Thousand USD | 8.36% |
| 2001 | 695.12 Thousand USD | 10.66% |
| 2000 | 628.17 Thousand USD | 26.1% |
| 1999 | 498.16 Thousand USD | -2.1% |
| 1998 | 508.84 Thousand USD | 0.79% |
| 1997 | 504.87 Thousand USD | -2.1% |
| 1996 | 515.7 Thousand USD | 2.12% |
| 1995 | 505.01 Thousand USD | 17.36% |
| 1994 | 430.32 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 42.08 Million USD | -2.82% |
| 2024 Q2 | 40.12 Million USD | -4.66% |
| 2023 Q2 | 53.68 Million USD | -9.92% |
| 2023 FY | 43.3 Million USD | -52.12% |
| 2023 Q1 | 59.6 Million USD | -34.11% |
| 2023 Q3 | 50.49 Million USD | -5.95% |
| 2023 Q4 | 43.3 Million USD | -14.23% |
| 2022 Q4 | 90.45 Million USD | -32.45% |
| 2022 Q3 | 133.9 Million USD | -8.41% |
| 2022 Q2 | 146.2 Million USD | 9.61% |
| 2022 FY | 90.45 Million USD | -46.62% |
| 2022 Q1 | 133.38 Million USD | -21.3% |
| 2021 Q2 | 210.6 Million USD | -12.0% |
| 2021 FY | 169.47 Million USD | -6.68% |
| 2021 Q3 | 209.62 Million USD | -0.46% |
| 2021 Q1 | 239.3 Million USD | 31.77% |
| 2021 Q4 | 169.47 Million USD | -19.16% |
| 2020 Q2 | 205.53 Million USD | -23.49% |
| 2020 Q1 | 268.64 Million USD | 1.0% |
| 2020 Q3 | 177.29 Million USD | -13.74% |
| 2020 Q4 | 181.6 Million USD | 2.44% |
| 2020 FY | 181.6 Million USD | -31.72% |
| 2019 Q2 | 246.55 Million USD | 35.55% |
| 2019 FY | 265.98 Million USD | 25.47% |
| 2019 Q1 | 181.89 Million USD | -14.2% |
| 2019 Q4 | 265.98 Million USD | 6.41% |
| 2019 Q3 | 249.96 Million USD | 1.38% |
| 2018 Q2 | 171.89 Million USD | 39.8% |
| 2018 Q3 | 236.75 Million USD | 37.73% |
| 2018 Q4 | 211.98 Million USD | -10.46% |
| 2018 Q1 | 122.96 Million USD | -14.15% |
| 2018 FY | 211.98 Million USD | 48.0% |
| 2017 FY | 143.22 Million USD | 0.53% |
| 2017 Q4 | 143.22 Million USD | -10.68% |
| 2017 Q1 | 124.42 Million USD | -12.67% |
| 2017 Q2 | 106.87 Million USD | -14.1% |
| 2017 Q3 | 160.36 Million USD | 50.04% |
| 2016 FY | 142.47 Million USD | 93.24% |
| 2016 Q1 | 192.96 Million USD | 161.73% |
| 2016 Q2 | 176.58 Million USD | -8.49% |
| 2016 Q3 | 158.82 Million USD | -10.06% |
| 2016 Q4 | 142.47 Million USD | -10.29% |
| 2015 Q2 | 75.67 Million USD | -23.93% |
| 2015 Q3 | 90.45 Million USD | 19.53% |
| 2015 Q4 | 73.72 Million USD | -18.5% |
| 2015 Q1 | 99.48 Million USD | 68.39% |
| 2015 FY | 73.72 Million USD | 24.8% |
| 2014 Q2 | 44.43 Million USD | -17.06% |
| 2014 FY | 59.07 Million USD | -4.74% |
| 2014 Q1 | 53.56 Million USD | -13.62% |
| 2014 Q3 | 74.6 Million USD | 67.92% |
| 2014 Q4 | 59.07 Million USD | -20.81% |
| 2013 Q4 | 62.01 Million USD | -9.44% |
| 2013 FY | 62.01 Million USD | 965.92% |
| 2013 Q3 | 68.47 Million USD | 59.01% |
| 2013 Q2 | 43.06 Million USD | -2.55% |
| 2013 Q1 | 44.19 Million USD | 659.57% |
| 2012 Q2 | 4.87 Million USD | 227.82% |
| 2012 FY | 5.81 Million USD | 304.39% |
| 2012 Q1 | 1.48 Million USD | 3.42% |
| 2012 Q3 | 3.51 Million USD | -27.95% |
| 2012 Q4 | 5.81 Million USD | 65.54% |
| 2011 FY | 1.43 Million USD | 207.8% |
| 2011 Q4 | 1.43 Million USD | 19509.12% |
| 2011 Q3 | 7337.00 USD | 34.55% |
| 2011 Q2 | 5453.00 USD | 448.59% |
| 2011 Q1 | 994.00 USD | -99.79% |
| 2010 Q2 | 1.46 Million USD | 74.64% |
| 2010 FY | 467.41 Thousand USD | -44.99% |
| 2010 Q3 | 511.09 Thousand USD | -65.15% |
| 2010 Q4 | 467.41 Thousand USD | -8.55% |
| 2010 Q1 | 839.85 Thousand USD | -1.17% |
| 2009 FY | 849.76 Thousand USD | 1461.52% |
| 2009 Q3 | 689.9 Thousand USD | 8447.99% |
| 2009 Q2 | 8071.00 USD | -71.13% |
| 2009 Q4 | 849.76 Thousand USD | 23.17% |
| 2009 Q1 | 27.95 Thousand USD | -48.63% |
| 2008 Q2 | 121.61 Thousand USD | -71.66% |
| 2008 Q1 | 429.15 Thousand USD | -13.37% |
| 2008 FY | 54.41 Thousand USD | -89.01% |
| 2008 Q4 | 54.41 Thousand USD | -14.79% |
| 2008 Q3 | 63.86 Thousand USD | -47.48% |
| 2007 Q3 | 2.03 Million USD | 5.81% |
| 2007 Q1 | 1.92 Million USD | 3.08% |
| 2007 Q2 | 1.92 Million USD | -0.01% |
| 2007 FY | 495.36 Thousand USD | -73.47% |
| 2007 Q4 | 495.36 Thousand USD | -75.67% |
| 2006 Q4 | 1.86 Million USD | -0.32% |
| 2006 Q3 | 1.87 Million USD | 10.82% |
| 2006 FY | 1.86 Million USD | 3.3% |
| 2006 Q2 | 1.69 Million USD | 9.15% |
| 2006 Q1 | 1.54 Million USD | -14.33% |
| 2005 Q4 | 1.8 Million USD | 28.67% |
| 2005 Q1 | 1.18 Million USD | 8.65% |
| 2005 FY | 1.8 Million USD | 66.05% |
| 2005 Q3 | 1.4 Million USD | 18.77% |
| 2005 Q2 | 1.18 Million USD | 0.01% |
| 2004 Q3 | 1.03 Million USD | 9.32% |
| 2004 Q1 | 922.98 Thousand USD | 2.76% |
| 2004 Q2 | 950.03 Thousand USD | 2.93% |
| 2004 FY | 1.08 Million USD | 21.19% |
| 2004 Q4 | 1.08 Million USD | 4.81% |
| 2003 Q3 | 857.6 Thousand USD | 4.63% |
| 2003 Q4 | 898.22 Thousand USD | 4.74% |
| 2003 Q2 | 819.67 Thousand USD | 1.31% |
| 2003 Q1 | 809.04 Thousand USD | 7.41% |
| 2003 FY | 898.22 Thousand USD | 19.25% |
| 2002 Q1 | 713.22 Thousand USD | 2.6% |
| 2002 Q4 | 753.21 Thousand USD | 7.29% |
| 2002 Q3 | 702.05 Thousand USD | 1.51% |
| 2002 Q2 | 691.63 Thousand USD | -3.03% |
| 2002 FY | 753.21 Thousand USD | 8.36% |
| 2001 Q4 | 695.12 Thousand USD | -5.0% |
| 2001 Q1 | 671.91 Thousand USD | 6.96% |
| 2001 FY | 695.12 Thousand USD | 10.66% |
| 2001 Q2 | 704.4 Thousand USD | 4.84% |
| 2001 Q3 | 731.68 Thousand USD | 3.87% |
| 2000 Q4 | 628.17 Thousand USD | 11.72% |
| 2000 Q3 | 562.25 Thousand USD | 6.44% |
| 2000 Q2 | 528.25 Thousand USD | 2.53% |
| 2000 Q1 | 515.21 Thousand USD | 3.42% |
| 2000 FY | 628.17 Thousand USD | 26.1% |
| 1999 Q4 | 498.16 Thousand USD | 0.0% |
| 1999 FY | 498.16 Thousand USD | -2.1% |
| 1998 FY | 508.84 Thousand USD | 0.79% |
| 1997 FY | 504.87 Thousand USD | -2.1% |
| 1996 FY | 515.7 Thousand USD | 2.12% |
| 1995 FY | 505.01 Thousand USD | 17.36% |
| 1994 FY | 430.32 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Cosmos Health Inc. | 66.29 Million USD | 34.673% |
| Safety Shot Inc | 12.7 Million USD | -240.769% |
| Bright Green Corporation | 17.4 Million USD | -148.859% |
| Embecta Corp. | 1.21 Billion USD | 96.434% |
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 95.211% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | 24.572% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 96.212% |
| Dynavax Technologies Corporation | 997.09 Million USD | 95.656% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | 78.955% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | 94.053% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 97.249% |
| PainReform Ltd. | 9.93 Million USD | -336.143% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -58.369% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -58.369% |
| SCYNEXIS, Inc. | 128.41 Million USD | 66.273% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -87.266% |
| Journey Medical Corporation | 76.84 Million USD | 43.644% |
| Alpha Teknova, Inc. | 128.58 Million USD | 66.319% |
| Procaps Group, S.A. | 460.18 Million USD | 90.589% |
| Theratechnologies Inc. | 77.76 Million USD | 44.311% |
| Harrow Health, Inc. | 311.75 Million USD | 86.108% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -190.801% |
| Biofrontera Inc. | 27.93 Million USD | -55.052% |
| DURECT Corporation | 45.18 Million USD | 4.16% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 96.926% |
| Cronos Group Inc. | 1.13 Billion USD | 96.182% |
| OptiNose, Inc. | 107.72 Million USD | 59.798% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 90.806% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | 22.592% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -87.915% |
| Organogenesis Holdings Inc. | 460.02 Million USD | 90.586% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -263.386% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | 47.04% |
| Radius Health, Inc. | 1.71 Billion USD | 97.476% |
| Universe Pharmaceuticals INC | 53.28 Million USD | 18.725% |
| ProPhase Labs, Inc. | 91.92 Million USD | 52.888% |
| Phibro Animal Health Corporation | 982.18 Million USD | 95.591% |
| Procaps Group S.A. | 460.18 Million USD | 90.589% |
| Alvotech | 950.09 Million USD | 95.442% |
| Viatris Inc. | 47.68 Billion USD | 99.909% |
| Rockwell Medical, Inc. | 52.17 Million USD | 16.99% |
| Aytu BioPharma, Inc. | 118.09 Million USD | 63.327% |
| SIGA Technologies, Inc. | 254.83 Million USD | 83.005% |
| Tilray Brands, Inc. | 4.33 Billion USD | 99.001% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | 84.177% |
| Shineco, Inc. | 84.17 Million USD | 48.552% |
| PetIQ, Inc. | 868.22 Million USD | 95.012% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -413.249% |
| Incannex Healthcare Limited | 17.04 Million USD | -154.056% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 98.668% |
| Alimera Sciences, Inc. | 153.52 Million USD | 71.79% |
| Silver Spike Investment Corp. | 88.57 Million USD | 51.105% |
| Assertio Holdings, Inc. | 286.41 Million USD | 84.879% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -627.67% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -28.149% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | -38.62% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -226.921% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | 83.415% |
| Hempacco Co., Inc. | 18.04 Million USD | -140.031% |
| Talphera, Inc. | 20.39 Million USD | -112.351% |
| Alvotech | 950.09 Million USD | 95.442% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | 89.337% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 97.377% |
| Currenc Group, Inc. | 141.49 Million USD | 69.391% |
| Kamada Ltd. | 351.96 Million USD | 87.695% |
| Indivior PLC | 1.95 Billion USD | 97.78% |
| Evoke Pharma, Inc. | 7.06 Million USD | -512.7% |
| Flora Growth Corp. | 23.62 Million USD | -83.311% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -226.921% |
| Evolus, Inc. | 188.99 Million USD | 77.085% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 96.616% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 97.137% |
| Akanda Corp. | 8.83 Million USD | -389.921% |